|dc.description.abstract||Background. Whether rosiglitazone use in patients with type 2 diabetes may affect thyroid cancer risk has not been investigated. Methods. The reimbursement databases of all diabetic patients under oral anti-diabetic agents or insulin from 1996 to 2009 were retrieved from the National Health Insurance of Taiwan. An entry date was set at 1 January 2006, and 887,665 patients with type 2 diabetes were followed for thyroid cancer incidence until the end of 2009 for ever-users, never-users, and subgroups of rosiglitazone exposure using tertile cut-offs for time since starting rosiglitazone, duration of therapy, and cumulative dose. Hazard ratios were estimated by Cox regression. Results. There were 103,224 ever-users and 784,441 never-users, with respective numbers of incident thyroid cancer of 84 (0.08%) and 764 (0.10%), and respective incidence of 23.12 and 28.09 per 100,000 person-years. The overall multivariable-adjusted hazard ratio was not significant. However, in dose-response analyses, the adjusted hazard ratios (95% confidence intervals) were significant for the third tertile of duration of therapy (? 14 months) and cumulative dose (? 1,800 mg) for age ? 50 years: 0.53 (0.31-0.89) and 0.50 (0.29-0.87), respectively. Conclusions. This study suggests that rosiglitazone use in patients with type 2 diabetes may reduce the risk of thyroid cancer. ? 2013 Informa UK, Ltd.||-|
|dc.relation||Ann. Med., 45(8), 539-544||en|
|dc.relation.ispartof||Annals of Medicine||-|
|dc.subject.other||acarbose; acetylsalicylic acid; angiotensin receptor antagonist; calcium channel blocking agent; clopidogrel; dipeptidyl carboxypeptidase inhibitor; dipyridamole; fibric acid derivative; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; metformin; nonsteroid antiinflammatory agent; oral antidiabetic agent; pioglitazone; rosiglitazone; sulfonylurea; ticlopidine; adult; aged; article; cancer incidence; cancer risk; dose response; female; follow up; human; major clinical study; male; non insulin dependent diabetes mellitus; priority journal; thyroid cancer; treatment duration; Adult; Aged; Aged, 80 and over; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Taiwan; Thiazolidinediones; Thyroid Neoplasms; Treatment Outcome||-|
|dc.title||Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes||-|
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.